This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Epstein, S. E. Articles by Pastan, I. Search for Related Content PubMed PubMed Citation Articles by Epstein, S. E. Articles by Pastan, I.

Circulation, Vol 84, 778-787, Copyright © 1991 by American Heart Association

ARTICLES

Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells

SE Epstein, CB Siegall, S Biro, YM Fu, D FitzGerald and I Pastan
Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.

BACKGROUND. Restenosis after percutaneous transluminal coronary angioplasty is associated with activation of medial smooth muscle cells (SMCs); they proliferate, migrate to the subintima, and narrow the vessel lumen. Cancer cells often express more cell surface receptors than do normal cells. This has allowed tumor cells to be specifically targeted using cytotoxic agents. We have examined whether a similar concept can be applied to rapidly proliferating but nontransformed SMCs. Pseudomonas exotoxin (PE; MW, 66 kDa) is a potent toxin that kills cells by inhibiting protein synthesis; its toxicity is diminished when its cell recognition domain is deleted to produce a 40-kDa protein (PE40). METHODS AND RESULTS. A complementary DNA encoding transforming growth factor alpha (TGF alpha) was ligated to that encoding PE40 and the chimeric toxin TGF alpha-PE40, which is cytotoxic to cancer cells displaying epidermal growth factor (EGF) receptors, was expressed in Escherichia coli. The ability of this toxin to kill proliferating SMCs was tested. When cells were seeded at low density (2,500 cells/cm2) and grown in medium supplemented with 10% fetal bovine serum, they were found to be rapidly proliferating; these cells were very sensitive to the cytotoxic effects of TGF alpha-PE40 (ID50, 4.0 +/- 0.17 ng/ml). In contrast, cytotoxicity was 30-fold less (ID50, 125 +/- 23 ng/ml; p less than 0.0004) when cells were in a quiescent state (grown in medium supplemented with 0.5% fetal bovine serum). CONCLUSIONS. Competition studies using excess EGF indicated that the cytotoxic effects of TGF alpha-PE40 are specifically mediated by the EGF receptor. EGF receptor binding analysis demonstrated that rapidly proliferating SMCs display 10-fold more EGF receptors than do quiescent SMCs in vitro. Thus, a chimeric toxin targeted toward the EGF receptor can selectively kill rapidly proliferating SMCs. Whether this toxin or other chimeric toxins directed against other cell surface receptors will effectively inhibit SMCs proliferating in vivo or be useful in preventing restenosis remains to be determined.

This article has been cited by other articles:

				A. L Clark Exercise and heart failure: assessment and treatment. Heart, May 1, 2006; 92(5): 699 - 703. [Full Text] [PDF]

				J. C. Henry, M. M. Bonar, P. N. Kearns, H. Cui, M. M. Mutchler, M. V. Martin, A. R. Orsini, H. L. Elford, C. A. Bush, J. L. Zweier, et al. Inhibition of Ribonucleotide Reductase Reduces Neointimal Formation following Balloon Injury J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 70 - 76. [Abstract] [Full Text] [PDF]

				S.-I. Miyatake, H. Yukawa, H. Toda, N. Matsuoka, R. Takahashi, N. Hashimoto, and C. D. Kontos Inhibition of Rat Vascular Smooth Muscle Cell Proliferation In Vitro and In Vivo by Recombinant Replication-Competent Herpes Simplex Virus • Editorial Comment Stroke, November 1, 1999; 30 (11): 2431 - 2439. [Abstract] [Full Text] [PDF]

				J. Waltenberger Modulation of Growth Factor Action : Implications for the Treatment of Cardiovascular Diseases Circulation, December 2, 1997; 96(11): 4083 - 4094. [Abstract] [Full Text]

				K. Fukuda, S. Kawata, Y. Inui, S. Higashiyama, Y. Matsuda, T. Igura, S. Tamura, N. Taniguchi, and Y. Matsuzawa High Concentration of Glucose Increases Mitogenic Responsiveness to Heparin-Binding Epidermal Growth Factor–like Growth Factor in Rat Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, October 1, 1997; 17(10): 1962 - 1968. [Abstract] [Full Text]

				A. Farb, S. J. Lee, D. H. Min, Z. Parandoosh, J. Cook, J. McDonald, G. F. Pierce, and R. Virmani Vascular Smooth Muscle Cell Cytotoxicity and Sustained Inhibition of Neointimal Formation by Fibroblast Growth Factor 2–Saporin Fusion Protein Circ. Res., April 19, 1997; 80(4): 542 - 550. [Abstract] [Full Text]

				T. Igura, S. Kawata, J.-i. Miyagawa, Y. Inui, S. Tamura, K. Fukuda, K. Isozaki, K. Yamamori, N. Taniguchi, S. Higashiyama, et al. Expression of Heparin-Binding Epidermal Growth Factor–Like Growth Factor in Neointimal Cells Induced by Balloon Injury in Rat Carotid Arteries Arterioscler Thromb Vasc Biol, December 1, 1996; 16(12): 1524 - 1531. [Abstract] [Full Text]

				C. Chen, S. G. Mattar, J. D. Hughes, G. F. Pierce, J. E. Cook, D. N. Ku, S. R. Hanson, and A. B. Lumsden Recombinant Mitotoxin Basic Fibroblast Growth Factor–Saporin Reduces Venous Anastomotic Intimal Hyperplasia in the Arteriovenous Graft Circulation, October 15, 1996; 94(8): 1989 - 1995. [Abstract] [Full Text]

				K. A. Peifley, G. F. Alberts, D. K.W. Hsu, S.-L. Y. Feng, and J. A. Winkles Heparin-Binding Epidermal Growth Factor-Like Growth Factor Regulates Fibroblast Growth Factor-2 Expression in Aortic Smooth Muscle Cells Circ. Res., August 1, 1996; 79(2): 263 - 270. [Abstract] [Full Text]

				C. Duan, S. B. Hawes, T. Prevette, and D. R. Clemmons Insulin-like Growth Factor-I (IGF-I) Regulates IGF-binding Protein-5 Synthesis through Transcriptional Activation of the Gene in Aortic Smooth Muscle Cells J. Biol. Chem., February 23, 1996; 271(8): 4280 - 4288. [Abstract] [Full Text] [PDF]

				K. Fukuda, Y. Inui, S. Kawata, S. Higashiyama, Y. Matsuda, Y. Maeda, T. Igura, S. Yoshida, N. Taniguchi, and Y. Matsuzawa Increased Mitogenic Response to Heparin-Binding Epidermal Growth Factor–like Growth Factor in Vascular Smooth Muscle Cells of Diabetic Rats Arterioscler Thromb Vasc Biol, October 1, 1995; 15(10): 1680 - 1687. [Abstract] [Full Text]

				C. J. Pastore, J. M. Isner, P. A. Bacha, M. Kearney, and J. G. Pickering Epidermal Growth Factor Receptor–Targeted Cytotoxin Inhibits Neointimal Hyperplasia In Vivo : Results of Local Versus Systemic Administration Circ. Res., September 1, 1995; 77(3): 519 - 529. [Abstract] [Full Text]

				E. G. Nabel Gene Therapy for Cardiovascular Disease Circulation, January 15, 1995; 91(2): 541 - 548. [Full Text]

				E. Mesri, M Ono, R. Kreitman, M Klagsbrun, and I Pastan The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans J. Cell Sci., January 9, 1994; 107(9): 2599 - 2608. [Abstract] [PDF]